Syntekabio to Showcase AI-Driven Drug Discovery Solutions at BioTechX USA
TL;DR
Syntekabio is the Title Sponsor and will give a keynote address at BioTechX USA, positioning itself as a leader in AI-driven drug development.
Syntekabio's AI-driven technologies enable pharmaceutical and biotech companies to test the validity of target proteins without upfront costs, followed by STB LaunchPad program for delivering validated results.
Syntekabio's AI-driven solutions improve and accelerate R&D activities, offering potential hits and optimized leads in drug discovery, antibody prediction, and cancer neoantigen discovery to develop novel and effective therapeutics.
Syntekabio's participation at BioTechX USA includes a keynote presentation on addressing data scarcity in drug discovery with AI models, and a session on flexible molecular docking for neoantigen and antibody drug prediction.
Found this article helpful?
Share it with your network and spread the knowledge!
Syntekabio (KOSDAQ: 226330), an artificial intelligence (AI) based drug development company, has announced its participation in BioTechX USA, scheduled for September 17-18, 2024, in Philadelphia, PA. As the Title Sponsor, Syntekabio will deliver a keynote address and host a booth to highlight its AI-driven solutions for drug discovery and development.
According to Jongsun Jung, PhD, CEO of Syntekabio, the company's technologies aim to enhance and expedite R&D activities for potential clients. Syntekabio's recently introduced 'Develop Now, Pay Later' offer allows clients to test target protein validity without upfront costs, potentially lowering financial barriers for early-stage drug discovery.
Syntekabio's AI-driven platform, DeepMatcher®, powers their STB LaunchPad program, which provides hits, optimized leads, and IND-enabled candidates. This technology is designed to accelerate the drug discovery process, making it more efficient and cost-effective. Clients only pay for the services upon obtaining validated results, which could revolutionize how pharmaceutical companies approach early-stage research.
In addition to small molecule lead optimization, Syntekabio boasts strong capabilities in antibody and cancer neoantigen discovery. At BioTechX USA, the company will present on topics such as addressing data scarcity in drug discovery using physics-based AI models and flexible molecular docking for neoantigen and antibody drug prediction.
Syntekabio's AI platforms, Neo-ARS™ and Ab-ARS™, enable the prediction of personalized or universal neoantigen cancer vaccines and novel antibody drugs. These tools provide researchers with advanced capabilities to tackle complex challenges in drug discovery, potentially leading to more effective therapeutics.
The company's AI technology leverages over 10 billion known compounds and 1,400 drug targets, covering over 70% of human diseases. This extensive database is powered by Syntekabio's AI Bio-Supercom Center, which comprises 5,000 servers, 40,000 CPU cores, and 2,500 GPUs, facilitating rapid and robust computational analysis.
By integrating AI and machine learning with drug discovery, Syntekabio aims to streamline the development of first-in-class and best-in-class compounds. The company's disease-agnostic platform consistently generates a pipeline of hits, leads, and drug candidates available for purchase, offering a comprehensive suite of services from target identification to IND-enabling stages.
Curated from News Direct
